

D
This application is a continuation-in-part of U.S. Patent Application No. 09/443,686, filed November 18, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/352,616, filed July 13, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/288,946, filed April 9, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/232,149, filed January 15, 1999, which is a continuation-in-part of U.S. Patent Application No. 09/159,812, filed September 23, 1998, which is a continuation-in-part of U.S. Patent Application No. 09/115,453, filed July 14, 1998, which is a continuation-in-part of U.S. Patent Application No. 09/030,607, filed February 25, 1998, which is a continuation-in-part of U.S. Patent Application No. 09/020,956, filed February 9, 1998, which is a continuation-in-part of U.S. Patent Application No. 08/904,804, filed August 1, 1997, which is a continuation-in-part of U.S. Patent Application No. 08/806,099, filed February 25, 1997.

In the Claims:

Please cancel claims 66-71.

Please amend claim 72 to read as follows:

D2
72. (Amended) A composition comprising an immunostimulant and an isolated polypeptide having at least 90% identity to the entirety of SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T-cells.

Please add new claims 73-78 set forth below.

D3
73. (New) A composition comprising an immunostimulant and an isolated polypeptide having at least 90% identity to a polypeptide comprising amino acids 1-39 of SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T-cells.

74. (New) A composition comprising an immunostimulant and an isolated polypeptide comprising SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T-cells.

D3
CON'T.

75. (New) A composition comprising an immunostimulant and an isolated polypeptide comprising amino acids 1-39 of SEQ ID NO: 525, wherein the polypeptide contains an amino acid sequence capable of stimulating human T-cells.

76. (New) The composition according to claim 72, wherein the polypeptide has at least 95% identity to the entirety of SEQ ID NO: 525.

77. (New) The composition according to any one of claims 72-76, wherein the immunostimulant is selected from the group consisting of a monophosphoryl lipid A, a CpG-containing oligonucleotide, a saponin, or a combination thereof.

78. (New) The composition according to any one of claims 72-76, wherein the immunostimulant is selected from the group consisting of 3D-MPL, QS21, or a combination thereof.

79. (New) The composition according to any one of claims 72-76, wherein the immunostimulant comprises 3D-MPL, QS21 and tocopherol in an oil-in-water emulsion.

REMARKS

Favorable reconsideration of the instant application in view of the present amendment and the following comments is respectfully requested. Claims 21-22 and 65-72 are under examination in this application. Claim 72 has been amended and claims 66-71 have been cancelled. Claims 73-79 are newly added. Support for the above amendment can be found throughout the specification, for example, at page 36, line 10; page 4, lines 20-25; page 45, line 26; page 45, line 26 to page 47, line 12, and elsewhere. In addition, the specification has been amended, as suggested by the Examiner, by updating the CROSS REFERENCE TO RELATED APPLICATIONS. It should be noted that the above amendments are not to be construed as acquiescence with regard to the Examiner's rejections and are made without prejudice to prosecution of any subject matter modified and/or removed by this amendment in a related divisional, continuation and/or continuation-in-part application.